Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC

Clinical trial NCT06173505 · TERMINATED

Trial details

NCT number: NCT06173505
Sponsor: Xencor, Inc.
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Nonsquamous Non-small Cell Lung Cancer

Start date: 2023-12-27
Primary completion: 2025-12-24
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.